InflaRx (NASDAQ:IFRX) Sees Significant Increase in Short Interest

InflaRx (NASDAQ:IFRX - Get Free Report) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 262,900 shares, a growth of 63.2% from the September 15th total of 161,100 shares. Based on an average daily volume of 59,400 shares, the days-to-cover ratio is presently 4.4 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of InflaRx in a report on Wednesday, September 25th.

Hedge Funds Weigh In On InflaRx

A hedge fund recently raised its stake in InflaRx stock. Ikarian Capital LLC raised its holdings in InflaRx (NASDAQ:IFRX - Free Report) by 2.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 704,987 shares of the company's stock after buying an additional 16,383 shares during the quarter. Ikarian Capital LLC owned approximately 1.20% of InflaRx worth $1,086,000 at the end of the most recent quarter. Institutional investors and hedge funds own 42.39% of the company's stock.

InflaRx Trading Down 0.7 %

InflaRx stock traded down $0.01 during midday trading on Monday, reaching $1.50. 54,845 shares of the stock traded hands, compared to its average volume of 158,385. The firm has a market cap of $88.32 million, a PE ratio of -1.92 and a beta of 1.57. The company has a 50-day simple moving average of $1.49 and a two-hundred day simple moving average of $1.50. InflaRx has a 12-month low of $1.14 and a 12-month high of $2.46.

InflaRx (NASDAQ:IFRX - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). InflaRx had a negative net margin of 44,046.09% and a negative return on equity of 47.03%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.04 million. Equities research analysts anticipate that InflaRx will post -0.98 earnings per share for the current year.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.